HIV medical providers' perceptions of the use of antiretroviral therapy as nonoccupational postexposure prophylaxis in 2 major metropolitan areas

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue SUPPL. 1, 2013, Pages

  Rodríguez, Allan E ^a   Castel, Amanda D ^b   Parish, Carrigan L ^c   Willis, Sarah ^b   Feaster, Daniel J ^a   Kharfen, Michael ^d   Cardenas, Gabriel A ^d   Villamizar, Kira ^e   Kolber, Michael ^a   Vázquez Rivera, Liliana ^a   Metsch, Lisa R ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Columbia University ^*  (United States)

^d District of Columbia Department of Health   (United States)

^e Miami Dade County   (United States)

Author keywords

Antiretroviral prophylaxis; HIV medical providers; HIV prevention; Nonoccupational exposure

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HEALTH BELIEF; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH PERSONNEL ATTITUDE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE; MEDICAL PRACTICE; POST EXPOSURE PROPHYLAXIS; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; UNITED STATES;

ADULT; ANTI-HIV AGENTS; ATTITUDE OF HEALTH PERSONNEL; DISTRICT OF COLUMBIA; FEMALE; FLORIDA; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; UNITED STATES; URBAN POPULATION;

EID: 84886552623     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a901a2     Document Type: Conference Paper

References (55)

1. Centers for Disease Control and Prevention. HIV in the United States: at a glance. Available at: http://www.cdc.gov/hiv/pdf/statistics-basics- factsheet.pdf. Accessed May 22, 2013.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
3. Grant R, Lama J, Anderson P, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363: 2587-2599.
4. Thigpen M, Kebaabetswe P, Paxton L, et al. Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367: 423-434.
5. Tissot F, Erard V, Dang T, et al. Non-occupational HIV post-exposure prophylaxis: a 10-year retrospective analysis. HIV Med. 2010;11: 584-592.
6. Otten R, Smith D, Adams D, et al. Efficacy of post-exposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol. 2000;74: 9771-9775.
7. Tsai C, Emau P, Follis K, et al. Effectiveness of post-inoculation (R)-9- (2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72: 4265-4273.
8. Mori K, Yasutomi Y, Sawada S, et al. Suppression of acute viremia by short-term post-exposure prophylaxis of simian/human immunodefi- ciency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol. 2000;74: 5747-5753.
9. Sperling R, Shapiro D, Coombs R, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996;335: 1621-1629.
10. Cardo D, Culver D, Ciesielski C, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337: 1485-1490.
11. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1994-August 1994. MMWR Morb Mortal Wkly Rep. 1995;444: 929-933.
12. Katzenstein T, Dickmeiss E, Aladdin H, et al. Failure to develop HIV infection after receipt of HIV-contaminated blood and post-exposure prophylaxis. Ann Intern Med. 2000;133: 31-34.
13. Bloch M, Carr A, Vasak E, et al. The use of human immunodeficiency virus post-exposure prophylaxis after successful artificial insemination. Am J Obstet Gynecol. 1999;181: 760-761.
14. Kunches L, Meehan T, Boutwell R, et al. Survey of non-occupational HIV post-exposure prophylaxis in hospital emergency departments. J Acquir Immune Defic Syndr. 2001;26: 263-265.
15. Centers for Disease Control and Prevention. Antiretroviral post-exposure prophylaxis after sexual, injection-drug use, or other non-occupational exposure to HIV in the United States. MMWR Recomm Rep. 2005;54: 1-20.
16. Merchant R, Becker B, Mayer K, et al. Emergency department blood or body fluid exposure evaluations and HIV post-exposure prophylaxis usage. Acad Emerg Med. 2003;10: 1345-1353.
17. Shoptaw S, Rotheram-Fuller E, Landovitz RJ, et al. Non-occupational post-exposure prophylaxis as a biobehavioral HIV-prevention intervention. AIDS Care. 2008;20: 376-381.
18. Lurie P, Miller S, Hecht F, et al. Post-exposure prophylaxis after nonoccupational HIV exposure. JAMA. 1998;280: 1769-1773.
19. Richens J, Edwards S, Sadiq S. Can the promotion of post-exposure prophylaxis following sexual exposure to HIV (PEPSE) cause harm? Sex Transm Infect. 2005;81: 190-191.
20. Kahn J, Martin J, Roland M, et al. Feasibility of post-exposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study. J Infect Dis. 2001;183: 707-714.
21. Low-Beer S, Weber A, Bartholomew K, et al. A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk. AIDS. 2000;14: 325-326.
22. Pinkerton S, Holtgrave D, Bloom F. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. AIDS. 1998;12: 1067-1078.
23. Spence J. Should emergency departments offer post-exposure prophylaxis for non-occupational exposure to HIV? CJEM. 2003;5: 38-45.
24. Pinkerton S, Martin J, Roland M, et al. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS. 2004;18: 2065-2073.
25. Martin JN, Roland ME, Neilands TB, et al. Use of post-exposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behaviour. AIDS. 2004;18: 787-792.
26. Mayer K, Mimiaga M, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for non-occupational post-exposure prophylaxis (NPEP) in a Boston community health center. J Acquir Immune Defic Syndr. 2008; 47: 494-499.
27. Donnell D, Mimiaga M, Mayer K, et al. Use of non-occupational postexposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial. AIDS Behav. 2010;14: 1182-1189.
28. Poynten I, Jin F, Mao L, et al. Non-occupational post-exposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS. 2009;23: 1119-1126.
29. Schechter M, Do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to post-exposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35: 519-525.
30. Liu A, Kittredge P, Vittinghoff E, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008;47: 241-247.
31. Voetsch A, Heffelfinger J, Begley E, et al. Knowledge and use of preexposure and post exposure prophylaxis among attendees of minority gay pride events, 2005 through 2006. J Acquir Immune Defic Syndr. 2007;46: 378-380.
32. Mehta SA, Silvera R, Bernstein K, et al. Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sex Transm Infect. 2011;87: 344-347.
33. Ende A, Hein L, Sottolano D, et al. Non-occupational post-exposure prophylaxis for exposure to HIV in New York state emergency departments. AIDS Patient Care STDs. 2008;22: 797-802.
34. Merchant R, Keshavarz R. Emergency prophylaxis following needlestick injuries and sexual exposures: results from a survey comparing New York emergency department practitioners with their national colleagues. Mt Sinai J Med. 2003;70: 338.
35. Landovitz RJ, Combs K, Currier J. Availability of HIV post exposure prophylaxis services in Los Angeles County. Clin Infect Dis. 2009;48: 1624-1627.
36. Centers for Disease Control and Prevention. Enhanced Comprehensive HIV Prevention Planning and Implementation for metropolitan areas most affected by HIV/AIDS. CDC Home Web site. Available at: http://www.cdc.gov/hiv/prevention/ demonstration/echpp/index.html. Accessed May 22, 2013.
37. AIDS.gov. Post-exposure prophylaxis. Available at: http://aids.gov/hiv- aids-basics/prevention/reduce-your-risk/post-exposure-prophylaxis/. Accessed June 19, 2013.
38. Dillman D. Mail and Telephone Surveys: The Total Design Method. New York, NY: John Wiley & Sons Inc; 1978.
39. McCausland J, Linden J, Degutis L, et al. Non-occupational post-exposure HIV prevention: emergency physicians' current practices, attitudes, and beliefs. Ann Emerg Med. 2003;42: 651-656.
40. Merchant R, Keshavarz R. HIV post-exposure prophylaxis practices by US ED practitioners. Ann Emerg Med. 2003;21: 309-312.
41. Enders C. Applied Missing Data Analysis. New York, NY: The Guilford Press; 2010.
42. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16: 219-242.
43. van Buuren S, Brand JPL, Groothuis-Oudshoorn CGM, et al. Fully conditional specification in multiple imputation. J Stat Comput Simul. 2006; 76: 1049-1064.
44. Graham J, Olchowski AE, Gilreath T. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci. 2007;8: 206-213.
45. Lalota M, Beck D, Metsch L, et al. HIV seropositivity and correlates of infection among heterosexually active adults in high-risk areas in South Florida. AIDS Behav. 2011;15: 1259-1263.
46. Magnus M, Kuo I, Shelley K, et al. Risk factors driving the emergence of a generalized heterosexual HIV epidemic in Washington, District of Columbia networks at risk. AIDS. 2009;23: 1277-1284.
47. Magnus M, Kuo I, Phillips G, et al. Elevated HIV prevalence despite lower rates of sexual risk behaviors among black men in the District of Columbia who have sex with men. AIDS Patient Care STDS. 2010;24: 615-622.
48. Centers for Disease Control and Prevention. HIV Surveillance Report, 2011, Volume 23. Available at: http://www.cdc.gov/hiv/topics/surveillance/ resources/reports/. Accessed June 19, 2013.
49. Southern AIDS Coalition. Southern States Manifesto: Update 2012, Policy and Recommendations. Available at: http://www.southernaidscoalition.org/. Accessed June 19, 2013.
50. Government of the District of Columbia Department of Health. DC DOH annual report, District of Columbia HIV/AIDS epidemiology update. Available at: http://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/ HAHSTA-ANNUAL-REPOR-2011. Accessed September 14, 2012.
51. Centers for Disease Control and Prevention. The 12 cities project. Available at: http://www.cdc.gov/hiv/prevention/demonstration/echpp/. Accessed June 19, 2013.
52. Magnus M, Kuo K, Phillips G, et al. Differing HIV risks and prevention needs among men and women injection drug users (IDU) in the District of Columbia. J Urban Health. 2013;90: 157-166.
53. Fenway Health. Possible HIV exposure? It may be time to "Talk PEP". Available at: http://fenwayfocus.org/2013/06/talkpep/. Accessed June 19, 2013.
54. Cahill S. Policy Focus: Pre-exposure Prophylaxis for HIV Prevention: Moving Toward Implementation. 2nd ed. Boston, MA: The Fenway Institute; 2012.
55. Underhill K, Operario D, Skeer M, et al. Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr. 2010;55: 8-13.